NEW YORK, Sept. 13 /PRNewswire-FirstCall/ -- Pfizer Inc said today that the District Court of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin -- the active ingredient in Lipitor -- would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to appeal, prevents Ranbaxy from launching its drug before Lipitor’s basic patent (EP 247,633) expires in November 2011.
